For GA, secondary to AMD

NAVIGATING PRODUCT ACQUISITION

How to order SYFOVRE️
Man looking at the camera

Acquiring product for your patients should not be a hassle.

Our goal is to simplify ordering logistics so you can focus on what matters—providing exceptional patient care.

Ordering information

SYFOVRE is available through 2 distribution channels:

Specialty distributors for buy and bill
AmerisourceBergen (Besse Medical)

Phone: 800-543-2111 Fax: 800-543-8695 Email: service@besse.com Website: besse.com/contact-us

BioCare

Phone: 855-202-6699 Email: customercare@biocaresd.com Website: biocare-us.com

Cardinal Health™  (Metro Medical™)

Phone: 800-768-2002 Email: customersvc@cardinalhealth.com Website: metromedicalorder.com

CuraScript® SD

Phone: 877-599-7748 Fax: 800-862-6208 Email: customer.service@curascript.comWebsite: order.curascriptsd.com

McKesson Plasma & Biologics for Health Systems and Hospitals

Phone: 877-625-2566 Fax: 888-752-7626 Email: mpborders@mckesson.comWebsite: connect.mckesson.com

McKesson Specialty Health for Physician Clinics

Phone: 855-477-9800 Fax: 800-800-5673 Email: mshcustomercare-mspl@mckesson.com Website: mscs.mckesson.com

Specialty pharmacies
Accredo® Specialty Pharmacy

Phone: 800-803-2523 Fax: 888-302-1028 (to fax a referral) Website: accredo.comE-prescribing is also available.

CenterWell Specialty Pharmacy™

Phone: 800-486-2668 Fax: 877-405-7940 Website: centerwellspecialtypharmacy.com

E-prescribing is also available. Select “CenterWell Specialty Pharmacy” in e-prescribing software.

Optum Specialty Pharmacy

Phone: 855-427-4682 Fax: 877-342-4596 Website: specialty.optumrx.com

Apellis does not recommend the use of any particular listed distributor or pharmacy.

“Buy and bill” or specialty pharmacy?

SYFOVRE is typically acquired via buy and bill, which means your office buys the product from a specialty distributor, administers the product, and then bills the payer. However, product is also available from the select specialty pharmacies listed above.

Consider the factors below to help select the appropriate acquisition method for your practice.

Buy and Bill

PAYER

  • Required by Medicare Fee-for-Service (FFS)

ORDERING AND SHIPMENT

  • SYFOVRE purchased from specialty distributor and shipped to office

INVENTORY

  • Stock of SYFOVRE maintained by office to be used any time

Specialty Pharmacy (SP)

PAYER

  • May be required by some payers

ORDERING AND SHIPMENT

  • Prescription enrollment form sent to SP
  • Benefits verified and patient out-of-pocket (OOP) costs collected and processed by SP prior to shipping
  • SYFOVRE shipped from SP to office

INVENTORY

  • SYFOVRE to be used only for patient listed on shipment

Refer to the Product Ordering Guide for more information

DOWNLOADDownload resource

Looking for information about billing and coding for SYFOVRE?

NAVIGATE TO BILLING AND CODING

AMD=age-related macular degeneration; GA=geographic atrophy.

Back to top of page button Back to top of page button

IMPORTANT SAFETY INFORMATION 

INDICATION

CONTRAINDICATIONS

  • SYFOVRE is contraindicated in patients with ocular or periocular infections, in patients with active intraocular inflammation, and in patients with hypersensitivity to pegcetacoplan or any of the excipients in SYFOVRE. Systemic hypersensitivity reactions (e.g., anaphylaxis, rash, urticaria) have occurred.

SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

WARNINGS AND PRECAUTIONS

  • Endophthalmitis and Retinal Detachments

    • Intravitreal injections, including those with SYFOVRE, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering SYFOVRE to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.

  • Retinal Vasculitis and/or Retinal Vascular Occlusion

    • Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of SYFOVRE. Cases may occur with the first dose of SYFOVRE and may result in severe vision loss. Discontinue treatment with SYFOVRE in patients who develop these events. Patients should be instructed to report any change in vision without delay.

  • Neovascular AMD

    • In clinical trials, use of SYFOVRE was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (12% when administered monthly, 7% when administered every other month and 3% in the control group) by Month 24. Patients receiving SYFOVRE should be monitored for signs of neovascular AMD. In case anti-Vascular Endothelial Growth Factor (anti-VEGF) is required, it should be given separately from SYFOVRE administration.

  • Intraocular Inflammation

    • In clinical trials, use of SYFOVRE was associated with episodes of intraocular inflammation including: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, and anterior chamber flare. After inflammation resolves, patients may resume treatment with SYFOVRE.

  • Increased Intraocular Pressure

    • Acute increase in IOP may occur within minutes of any intravitreal injection, including with SYFOVRE. Perfusion of the optic nerve head should be monitored following the injection and managed as needed.

ADVERSE REACTIONS

  • Most common adverse reactions (incidence ≥5%) are ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, conjunctival hemorrhage.

INDICATION

SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Please see full Prescribing Information for more information